Unicycive Therapeutics (UNCY) Price & Analysis

Compare

701 Followers

UNCY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.83 - $11.00

Previous CloseN/A

Volume1.16M

Average Volume (3M)453.35K

Market Cap

$74.00M

Enterprise Value$36.76M

Total Cash (Recent Filing)$22.33M

Total Debt (Recent Filing)$476.00K

Price to Earnings (P/E)―

Beta1.52

Next Earnings

Nov 18, 2025

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding17,661,697

10 Day Avg. Volume590,640

30 Day Avg. Volume453,345

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.50

Enterprise Value/Revenue64.72

Enterprise Value/Gross Profit-328.24

Enterprise Value/Ebitda-0.93

Forecast

1Y Price Target

$41.25

Price Target Upside884.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Commercial StrategyConsidering the large market potential, a well-thought-out OLC commercial strategy, and committed funding from accredited investors, UNCY is attractive to a long-term investor.

FDA FeedbackThere are no concerns with the drug’s safety or efficacy, and FDA feedback has otherwise positively received OLC’s data package.

Market PotentialThere is an unmet medical need to manage hyperphosphatemia, and any delay does not lessen the market potential of OLC.

Bears Say

Approval DelaysUnicycive is currently awaiting FDA approval for its first product candidate, Oxylanthanum Carbonate, which is anticipated later this year.

Manufacturing IssuesThe FDA has identified a cGMP compliance-related deficiency with the company’s third-party manufacturing vendor.

Unicycive Therapeutics News

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

Unicycive Therapeutics (UNCY) announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for...

15d ago

UNCY

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

“Our team has made great progress in the second quarter, and we have requested a Type A meeting...

19d ago

UNCY

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

Unicycive has requested a Type A meeting with the FDA to discuss resolution of the CRL received in...

19d ago

UNCY

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

As of June 30, 2025, cash and cash equivalents totaled $22.3 million. The Company believes that it has...

19d ago

UNCY

Unicycive Faces Class Action Over FDA Misleading Claims

Unicycive Therapeutics, Inc., a biopharmaceutical company, is facing a class action lawsuit that could have significant implications for...

14d ago

UNCY

Unicycive Faces Securities Lawsuit Over Drug Claims

Unicycive Therapeutics ( ($UNCY) ) has provided an update. On August 15, 2025, Unicycive Therapeutics was named in...

15d ago

UNCY

Unicycive Therapeutics Raises $16.3 Million in Stock Sale

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. Unicycive Therapeutics, Inc. sold 3,549,846 shares of common stock...

18d ago

UNCY

Unicycive Therapeutics: Buy Rating Amid FDA Compliance Resolution and Strong Financial Position

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, retaining the price target of...

18d ago

UNCY

Unicycive Therapeutics announces publication of OLC trial data

Unicycive Therapeutics (UNCY) announced the publication of trial data describing the safety and tolerability of oxylanthanum carbonate, OLC,...

1M ago

UNCY

Unicycive Regains Nasdaq Compliance After Stock Split

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. On July 8, 2025, Unicycive Therapeutics announced it regained...

2M ago

UNCY

Unicycive Therapeutics regains compliance with Nasdaq bid price requirement

Unicycive Therapeutics (UNCY) has regained compliance with Nasdaq continued listing standard for minimum share price. On July 7,...

2M ago

UNCY

Unicycive Therapeutics approval delay ‘not a surprise,’ says Noble Capital

The receipt of a Complete Response Letter in response to Unicycive’s New Drug Application for Oxylanthanum Carbonate was...

2M ago

UNCY

Unicycive Receives FDA CRL for New Drug Application

An update from Unicycive Therapeutics ( ($UNCY) ) is now available. On June 30, 2025, Unicycive Therapeutics announced...

2M ago

UNCY

H.C. Wainwright keeps Buy on Unicycive Therapeutics , says CRL ‘anticipated’

H.C. Wainwright analyst Swayampakula Ramakanth notes that Unicycive has announced the receipt of a complete response letter from...

2M ago

UNCY

UNCY FAQ

What was Unicycive Therapeutics’s price range in the past 12 months?

Unicycive Therapeutics lowest stock price was $2.83 and its highest was $11.00 in the past 12 months.

What is Unicycive Therapeutics’s market cap?

Unicycive Therapeutics’s market cap is $74.00M.

When is Unicycive Therapeutics’s upcoming earnings report date?

Unicycive Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 77 days.

How were Unicycive Therapeutics’s earnings last quarter?

Unicycive Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.683 by $0.163.

Is Unicycive Therapeutics overvalued?

According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unicycive Therapeutics pay dividends?

Unicycive Therapeutics does not currently pay dividends.

What is Unicycive Therapeutics’s EPS estimate?

Unicycive Therapeutics’s EPS estimate is -0.6.

How many shares outstanding does Unicycive Therapeutics have?

Unicycive Therapeutics has 17,661,697 shares outstanding.

What happened to Unicycive Therapeutics’s price movement after its last earnings report?

Unicycive Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.683. Following the earnings report the stock price went up 4.989%.

Which hedge fund is a major shareholder of Unicycive Therapeutics?

Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 0.

Unicycive Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-3987.11%

Trailing 12-Months

Asset Growth

-32.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics (UNCY) Earnings & Revenues

Historic Earnings Reports

UNCY Stock 12 Month Forecast

Average Price Target

$41.25

▲(884.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","121":"$121","31.75":"$31.8","61.5":"$61.5","91.25":"$91.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,31.75,61.5,91.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.2,13.107692307692307,22.015384615384615,30.923076923076923,39.830769230769235,48.73846153846154,57.64615384615385,66.55384615384615,75.46153846153847,84.36923076923078,93.27692307692308,102.18461538461538,111.0923076923077,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.2,7.05,9.899999999999999,12.75,15.599999999999998,18.45,21.299999999999997,24.149999999999995,26.999999999999996,29.849999999999998,32.699999999999996,35.55,38.4,{"y":41.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.2,4.338461538461539,4.476923076923077,4.615384615384616,4.753846153846154,4.892307692307693,5.030769230769231,5.1692307692307695,5.3076923076923075,5.446153846153846,5.584615384615384,5.723076923076923,5.861538461538462,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >